Welcome to the REVLIMID REMS^® program

Important information about REVLIMID and the REVLIMID Risk Evaluation
and Mitigation Strategy (REMS) program

• REVLIMID is contraindicated in pregnant females and females capable of becoming pregnant. Females of reproductive potential may be treated with REVLIMID provided adequate precautions are taken to avoid pregnancy

• To avoid embryo-fetal exposure, REVLIMID is only available under a restricted distribution program called "REVLIMID REMS^®"

• Only prescribers and pharmacies certified by the REVLIMID REMS^® program can prescribe and dispense REVLIMID to patients who are enrolled and meet all the conditions of the REVLIMID REMS^® program

The goals of the REVLIMID risk evaluation and mitigation strategy are as follows:

1. To prevent the risk of embryo-fetal exposure to REVLIMID

2. To inform prescribers, patients, and pharmacists on the serious risks and safe-use conditions for REVLIMID